Boston University Study Reveals Breakthrough in Diagnosing Brain Trauma

A landmark study from Boston University's CTE Center has made significant strides towards diagnosing chronic traumatic encephalopathy (CTE) in living individuals. The research, detailed in a study published in Molecular Neurodegeneration, shows a clear connection between the extent of CTE pathology, which is an accumulation of abnormal tau protein in the brain, and the severity of both cognitive and behavioral symptoms.

Provided a greater insight into the debilitating condition that is often found in athletes from high-contact sports, the research team analyzed the brains of 364 deceased individuals with autopsy-confirmed CTE. In a statement obtained by Boston University, coauthor Jesse Mez, who is also an associate professor of neurology at BU Chobanian & Avedisian School of Medicine and a codirector of clinical research at the CTE Center, described how, "For the first time, we were able to show a clear dose-response relationship between the amount of CTE pathology and the severity of cognitive and functional symptoms."

The participants' brains displayed varying amounts of p-tau, particularly within the frontal lobe, which correlated strongly with reported impairments in attention, memory, and perception. Friends and family of the deceased provided valuable data reflecting on their loved one's cognitive and behavioral issues, shedding light on the real-world impact of CTE. The study emphasized that p-tau pathology across the brain was associated with more reported cognitive functional symptoms, as opposed to neurobehavioral issues like impulse control, which was less correlated.

However, a hurdle for the research was its reliance on retrospective accounts from informants to gauge the severity of symptoms, as acknowledged by study coauthor Michael Alosco. Alosco, a BU Chobanian & Avedisian School of Medicine associate professor of neurology and CTE Center codirector of clinical research, emphasized, "We need to move toward a model where we objectively assess individuals during life and follow them until brain donation." Despite these challenges, the findings are a significant leap towards developing a viable in-life diagnosis for CTE, which has long been a goal for researchers and clinicians alike, as stated by the Boston University.

The Boston University team is hopeful that their efforts validate the symptom criteria, which currently have approval only for research purposes and not clinical diagnostics. Nonetheless, this breakthrough provides a promising foundation for future clinical trials aimed at identifying and possibly treating CTE in affected individuals while they are still alive. The study was backed by funding from the National Institutes of Health, National Center for Advancing Translational Sciences, Department of Veterans Affairs, and the Department of Defense.